THERMO FISHER SCIENTIFIC INC.
TMOAPI behind this page
TMO Q4 2025 request
Playground key active
/api/financials?ticker=TMO&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 12,215 | 11,395 | +7.2% |
Show Product Lines breakouts |
|||
| Consumables | 5,026 | 4,517 | +11.3% |
| Instruments | 2,221 | 2,250 | -1.3% |
| Product | 7,246 | 6,768 | +7.1% |
| Service | 4,969 | 4,627 | +7.4% |
Show Business Segments breakouts |
|||
| Analytical Instruments | 2,160 | 2,135 | +1.2% |
| Analytical Instruments · Chemical analysis | 339 | 339 | 0.0% |
| Analytical Instruments · Chromatography and mass spectrometry | 962 | 914 | +5.3% |
| Analytical Instruments · Electron microscopy | 914 | 932 | -1.9% |
| Analytical Instruments · Material Reconciling Items | 56 | 51 | +9.8% |
| Analytical Instruments · Operating Segments | 2,215 | 2,186 | +1.3% |
| Laboratory Products and Biopharma Services | 6,335 | 5,896 | +7.4% |
| Laboratory Products and Biopharma Services · Clinical research | 2,001 | 1,898 | +5.4% |
| Laboratory Products and Biopharma Services · Intersubsegment Eliminations | -241 | -234 | -3.0% |
| Laboratory Products and Biopharma Services · Laboratory products | 631 | 647 | -2.5% |
| Laboratory Products and Biopharma Services · Material Reconciling Items | 45 | 40 | +12.5% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,379 | 5,936 | +7.5% |
| Laboratory Products and Biopharma Services · Pharma services | 2,019 | 1,833 | +10.1% |
| Laboratory Products and Biopharma Services · Research and safety market channel | 1,969 | 1,794 | +9.8% |
| Life Sciences Solutions | 2,518 | 2,225 | +13.2% |
| Life Sciences Solutions · BioProduction | 966 | 749 | +29.0% |
| Life Sciences Solutions · Biosciences | 1,078 | 1,068 | +0.9% |
| Life Sciences Solutions · Genetic sciences | 794 | 786 | +1.0% |
| Life Sciences Solutions · Material Reconciling Items | 428 | 379 | +12.9% |
| Life Sciences Solutions · Operating Segments | 2,946 | 2,604 | +13.1% |
| Specialty Diagnostics | 1,202 | 1,139 | +5.5% |
| Specialty Diagnostics · Clinical diagnostics | 293 | 261 | +12.3% |
| Specialty Diagnostics · Healthcare market channel | 463 | 462 | +0.2% |
| Specialty Diagnostics · ImmunoDiagnostics | 231 | 215 | +7.4% |
| Specialty Diagnostics · Intersubsegment Eliminations | -68 | -66 | -3.0% |
| Specialty Diagnostics · Material Reconciling Items | 18 | 18 | 0.0% |
| Specialty Diagnostics · Microbiology | 172 | 162 | +6.2% |
| Specialty Diagnostics · Operating Segments | 1,220 | 1,157 | +5.4% |
| Specialty Diagnostics · Transplant diagnostics | 130 | 122 | +6.6% |
Show Geography breakouts |
|||
| Asia Pacific | 2,277 | 2,201 | +3.5% |
| Europe | 3,367 | 2,889 | +16.5% |
| North America | 6,109 | 5,864 | +4.2% |
| Other regions | 462 | 439 | +5.2% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -546 | -488 | -11.9% |
| Material Reconciling Items | 546 | 488 | +11.9% |
| Operating Segments | 12,761 | 11,883 | +7.4% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 3,722 | 3,334 | +11.6% |
| Service | 3,482 | 3,239 | +7.5% |
| Selling, General & Administrative | 2,352 | 2,203 | +6.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 305 | 317 | -3.8% |
| Laboratory Products and Biopharma Services · Operating Segments | 619 | 588 | +5.3% |
| Life Sciences Solutions · Operating Segments | 506 | 463 | +9.3% |
| Specialty Diagnostics · Operating Segments | 179 | 179 | 0.0% |
| Research & Development | 356 | 374 | -4.8% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 147 | 146 | +0.7% |
| Laboratory Products and Biopharma Services · Operating Segments | 15 | 16 | -6.2% |
| Life Sciences Solutions · Operating Segments | 145 | 148 | -2.0% |
| Specialty Diagnostics · Operating Segments | 44 | 48 | -8.3% |
| Restructuring And Other Costs Income Net | 46 | 228 | -79.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 46 | 228 | -79.8% |
| Total Costs & Expenses | 9,960 | 9,379 | +6.2% |
| Operating Income | 2,255 | 2,016 | +11.9% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 583 | 666 | -12.5% |
| Laboratory Products and Biopharma Services · Operating Segments | 925 | 828 | +11.7% |
| Life Sciences Solutions · Operating Segments | 1,046 | 952 | +9.9% |
| Specialty Diagnostics · Operating Segments | 324 | 273 | +18.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,878 | 2,720 | +5.8% |
| Interest Income | 258 | 227 | +13.7% |
| Interest Expense | -365 | -317 | -15.1% |
| Other Non-Operating Income (Expense) | 6 | 14 | -57.1% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 2,153 | 1,941 | +10.9% |
| Income Tax Expense (Benefit) | -153 | -150 | -2.0% |
| Income Loss From Equity Method Investments | -32 | 33 | -197.0% |
| Net Income | 1,970 | 1,824 | +8.0% |
| Net Income Loss Attributable To Noncontrolling Interest | 6 | -6 | +200.0% |
| Net Income | 1,964 | 1,830 | +7.3% |
| EPS (Basic) | 5.22 | 4.79 | +9.0% |
| EPS (Diluted) | 5.21 | 4.78 | +9.0% |
| Wtd Avg Shares (Basic) | -1 | 0 | — |
| Wtd Avg Shares (Diluted) | 0 | 0 | — |
| Cost of Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 1,137 | 1,003 | +13.4% |
| Laboratory Products and Biopharma Services · Operating Segments | 4,881 | 4,527 | +7.8% |
| Life Sciences Solutions · Operating Segments | 1,187 | 973 | +22.0% |
| Specialty Diagnostics · Operating Segments | 717 | 686 | +4.5% |
| Comprehensive Income | 2,316 | 1,610 | +43.9% |
| Gain Loss On Investments | 7 | 14 | -50.0% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 9,852 | 4,009 | +145.7% |
| Short-Term Investments | 253 | 1,561 | -83.8% |
| Accounts Receivable | 8,900 | 8,191 | +8.7% |
| Inventory | 5,425 | 4,978 | +9.0% |
| Contract With Customer Asset Net Current | 1,666 | 1,435 | +16.1% |
| Other Assets Current | 2,612 | 1,964 | +33.0% |
| Total Current Assets | 28,707 | 22,137 | +29.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 10,565 | 9,306 | +13.5% |
| Other Non-Current Assets | 5,871 | 4,492 | +30.7% |
| Goodwill | 49,362 | 45,853 | +7.7% |
Show Business Segments breakouts |
|||
| Analytical Instruments | 5,143 | 4,959 | +3.7% |
| Laboratory Products and Biopharma Services | 24,232 | 23,773 | +1.9% |
| Life Sciences Solutions | 14,910 | 12,336 | +20.9% |
| Specialty Diagnostics | 5,076 | 4,784 | +6.1% |
| Total Assets | 110,343 | 97,321 | +13.4% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 3,170 | 2,944 | +7.7% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,485 | 6,145 | +5.5% |
| Life Sciences Solutions · Operating Segments | 3,446 | 2,982 | +15.6% |
| Specialty Diagnostics · Operating Segments | 1,323 | 1,218 | +8.6% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 95,919 | 84,031 | +14.1% |
| Operating Lease Right-of-Use Assets | 1,447 | 1,489 | -2.8% |
| Intangible Assets | 14,604 | 14,298 | +2.1% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 12,775 | 12,596 | +1.4% |
| Developed Technology Rights | 1,305 | 1,134 | +15.1% |
| Order Or Production Backlog | 37 | 41 | -9.8% |
| Trade Names | 486 | 527 | -7.8% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 15,838 | 15,533 | +2.0% |
| Current Liabilities | |||
| Debt Current | 3,533 | 2,214 | +59.6% |
| Accounts Payable | 3,622 | 3,079 | +17.6% |
| Employee Related Liabilities Current | 1,995 | 1,988 | +0.4% |
| Deferred Revenue (Current) | 2,710 | 2,852 | -5.0% |
| Other Liabilities Current | 3,329 | 3,199 | +4.1% |
| Total Current Liabilities | 15,189 | 13,332 | +13.9% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 1,493 | 1,268 | +17.7% |
| Other Non-Current Liabilities | 4,273 | 3,989 | +7.1% |
| Long-Term Debt | 39,172 | 31,072 | +26.1% |
Show Long-Term Debt Type breakouts |
|||
| Other | 1 | 73 | -98.6% |
| Senior Notes | 39,171 | 30,999 | +26.4% |
| Operating Lease Liabilities | 1,195 | 1,239 | -3.6% |
| Contract With Customer Liability Noncurrent | 1,183 | 1,138 | +4.0% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 35,852 | 29,061 | +23.4% |
| Redeemable Noncontrolling Interest Equity Carrying Amount | 122 | 120 | +1.7% |
| Stockholders' Equity | |||
| Common Stock | 445 | 444 | +0.2% |
| Additional Paid In Capital Common Stock | 18,563 | 17,962 | +3.3% |
| Retained Earnings | 59,156 | 53,102 | +11.4% |
| Treasury Stock Common Value | -22,309 | -19,226 | -16.0% |
| Accumulated Other Comprehensive Income | -2,448 | -2,697 | +9.2% |
| Total Stockholders' Equity | 53,407 | 49,584 | +7.7% |
| Minority Interest | 7 | -33 | +121.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 53,415 | 49,551 | +7.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -245 | -263 | +6.8% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -23 | -25 | +8.0% |
| Accumulated Other Comprehensive Income | -2,448 | -2,697 | +9.2% |
| Accumulated Translation Adjustment | -2,181 | -2,409 | +9.5% |
| Additional Paid In Capital | 18,563 | 17,962 | +3.3% |
| Common Stock | 445 | 444 | +0.2% |
| Noncontrolling Interest | 7 | -33 | +121.2% |
| Parent | 53,407 | 49,584 | +7.7% |
| Retained Earnings | 59,156 | 53,102 | +11.4% |
| Treasury Stock Common | -22,309 | -19,226 | -16.0% |
| Total Liabilities & Equity | 110,343 | 97,321 | +13.4% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 292 | 304 | -3.9% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 28 | 27 | +3.7% |
| Laboratory Products and Biopharma Services · Operating Segments | 165 | 187 | -11.8% |
| Life Sciences Solutions · Operating Segments | 74 | 59 | +25.4% |
| Specialty Diagnostics · Operating Segments | 23 | 32 | -28.1% |
| Amortization Of Intangible Assets | 436 | 438 | -0.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 436 | 438 | -0.5% |
| Deferred Income Taxes | 89 | -202 | +144.1% |
| Stock-Based Compensation | 84 | 79 | +6.3% |
| Other Non-Cash Items | 140 | 254 | -44.9% |
| Net Cash from Operations | 3,457 | 3,290 | +5.1% |
| Investing Activities | |||
| Capital Expenditures | -465 | -480 | +3.1% |
| Proceeds From Sale Of Property Plant And Equipment | 27 | 17 | +58.8% |
| Proceeds From Payments For Cross Currency Interest Rate Swap Interest Settlements | 50 | 49 | +2.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | 0 | 0 | — |
| Payments To Acquire Investments | -32 | -1,331 | +97.6% |
| Proceeds From Sale Maturity And Collections Of Investments | 1,311 | 1,761 | -25.6% |
| Other Investing Activities | 1 | 3 | -66.7% |
| Net Cash from Investing | 891 | 20 | +4355.0% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 4,919 | 0 | — |
| Repayments Of Long Term Debt | -787 | -2,500 | +68.5% |
| Share Repurchases | -37 | -1,000 | +96.3% |
| Payments Of Dividends Common Stock | -162 | -149 | -8.7% |
| Proceeds From Payments For Other Financing Activities | 91 | -17 | +635.3% |
| Net Cash from Financing | 3,526 | -3,666 | +196.2% |
| Supplemental | |||
| Unpaid Capital Expenditures | 101 | 113 | -10.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -6 | -273 | +97.8% |
| Net Change in Cash | 7,868 | -630 | +1348.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 9,879 | 4,040 | +144.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.